Abstract
We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon α 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.
| Original language | English |
|---|---|
| Pages (from-to) | 1137-1139 |
| Number of pages | 3 |
| Journal | Oncology Reports |
| Volume | 3 |
| Issue number | 6 |
| Publication status | Published - 1996 |
Fingerprint
Keywords
- interferon α
- interleukin-2
- renal cancer
ASJC Scopus subject areas
- Cancer Research
- Oncology
Cite this
Interleukin-2 and interferon α 2 combination : Ineffectiveness of a single six-week course in patients with metastatic renal cancer pretreated with interferon alone. / Pronzato, Paolo.
In: Oncology Reports, Vol. 3, No. 6, 1996, p. 1137-1139.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Interleukin-2 and interferon α 2 combination
T2 - Ineffectiveness of a single six-week course in patients with metastatic renal cancer pretreated with interferon alone
AU - Pronzato, Paolo
PY - 1996
Y1 - 1996
N2 - We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon α 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.
AB - We have studied activity and toxicity of subcutaneous recombinant interleukin-2 and interferon α 2b in a series of 14 patients with advanced renal cell carcinoma. No objective response was observed, and the median survival was 16 months (range 3-19); toxicity was acceptable. All the patients had poor prognostic factors and were pretreated with interferon.
KW - interferon α
KW - interleukin-2
KW - renal cancer
UR - http://www.scopus.com/inward/record.url?scp=0029855083&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029855083&partnerID=8YFLogxK
M3 - Article
VL - 3
SP - 1137
EP - 1139
JO - Oncology Reports
JF - Oncology Reports
SN - 1021-335X
IS - 6
ER -